Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)

Jia Ruan • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Antibodies Lenalidomide Rituximab

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the clinical relevance of a phase II study of the biologic doublet, lenalidomide plus rituximab, as initial treatment for mantle cell lymphoma.

More from Jia Ruan

A trial of acalabrutinib, lenalidomide, and rituximab or obinutuzumab in treatment-naïve MCL
5:24
A trial of acalabrutinib, lenalidomide, and rituximab or obinutuzumab in treatment-naïve MCL
Jia Ruan • 9 Dec 2024
Long-term follow-up of a Phase II study combining azacitidine with CHOP in previously untreated PTCL
3:48
Long-term follow-up of a Phase II study combining azacitidine with CHOP in previously untreated PTCL
Jia Ruan • 9 Dec 2024
Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL
5:12
Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL
Jia Ruan • 10 Dec 2022
Emerging therapies in MCL: the promise of immunotherapies
6:56
Emerging therapies in MCL: the promise of immunotherapies
Jia Ruan • 4 Oct 2022

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals